

Brainwide mapping of endogenous serotonergic transmission via chemogenetic-fMRI

Andrea Giorgi^{1,2}, Sara Migliarini², Alberto Galbusera¹, Giacomo Maddaloni², Maddalena Mereu³, Giulia Margiani³, Marta Gritti⁴, Silvia Landi^{5,6}, Francesco Trovato^{5,6}, Sine Mandrup Bertozzi⁷, Andrea Armirotti⁷, Gian Michele Ratto^{5,6}, Maria Antonietta De Luca³, Raffaella Tonini⁴, Alessandro Gozzi^{1*}^A, Massimo Pasqualetti^{1,2*}

*Equal senior-author contribution

¹Functional Neuroimaging Laboratory, Center for Neuroscience and Cognitive systems, Istituto Italiano di Tecnologia, Rovereto, Italy

²Biology Department, University of Pisa, Pisa, Italy

³Department of Biomedical Sciences, University of Cagliari, 09124 Cagliari, Italy

⁴Neuroscience and Brain Technologies Department, Istituto Italiano di Tecnologia, Genova, Italy

⁵Institute Nanoscience, National Research Council, Pisa, Italy

⁶Scuola Normale Superiore, Pisa, Italy.

Lead contact and correspondence

Alessandro Gozzi, PhD

Functional Neuroimaging Laboratory

Istituto Italiano di Tecnologia

Center for Neuroscience and Cognitive Systems @ UNITN

Corso Bettini 31, 38068 Rovereto, Italy, Tel: +39 0464 808 701

^A Lead contact

alessandro.gozzi@iit.it

Running title: Chemo-fMRI of serotonergic transmission

SUMMARY

Serotonin-producing neurons profusely innervate brain regions via long-range projections. However, it remains unclear whether and how endogenous serotonergic transmission specifically influences regional or global functional activity. We combined DREADD-based chemogenetics and fMRI, an approach we term “*chemo-fMRI*”, to causally probe the brainwide substrates modulated by endogenous serotonergic activity. We describe the generation of a conditional knock-in mouse line that, crossed with serotonin-specific Cre-recombinase mice, allowed us to remotely stimulate serotonergic neurons during fMRI scans. We show that endogenous stimulation of serotonin-producing neurons does not affect global brain activity, but results in region-specific activation of a set of primary target regions encompassing cortico-hippocampal and ventro-striatal areas. By contrast, pharmacological boosting of serotonin levels produced widespread fMRI deactivation, plausibly reflecting the mixed contribution of central and perivascular constrictive effects. Our results identify the primary functional targets of endogenous serotonergic stimulation, and establish causation between activation of serotonergic neurons and regional fMRI signals.

Introduction

Serotonin (5-HT) is a modulatory transmitter produced by a small set of midbrain and brainstem nuclei that richly innervate forebrain target regions via long-range projections (Maddaloni et al., 2017). Such profuse innervation, along with the combined release of transmitters via pointwise synaptic signalling as well as non-synaptic 'volume transmission' (Descarries and Mechawar, 2000), can alter neuronal functions to define internal states that affect behavioural outputs in response to external stimuli. Recent research has shed light on the basic cellular and molecular machinery engaged by 5-HT (Lesch and Waider, 2012). However, many questions regarding the systems-level substrates modulated by 5-HT transmission remain unanswered. For one, it is unclear whether serotonin's modulatory action entails a global regulation of neural activity, or it is relayed and encoded by a set of primary functional targets.

Neuroimaging studies have employed pharmacological manipulations to probe the brainwide targets of 5-HT. The vast majority of these studies have primarily focused on the use of functional magnetic resonance imaging (fMRI) as a proxy for the neuronal activity directly elicited by pharmacological agents, or by mapping second-order modulatory effects on task-elicited fMRI responses (Anderson et al., 2008). This approach, termed pharmacological fMRI, has also been back-translated to animal studies (Klomp et al., 2012). However, while useful in identifying possible brainwide substrates of neuromodulatory action, drug-based approaches are often contaminated by off-target receptor contributions (Ofek et al., 2012), and often contain peripheral vasotonic or cerebrovascular contributions that cannot be easily disentangled from the drug's primary neural effects (Martin and Sibson, 2008). This aspect is especially relevant when hemodynamic measures of brain function are used, given that 5-HT can perivascularly modulate blood flow, independent of its central effects (Cohen et al., 1996). As a result, it remains unclear where and how endogenous

serotonergic activity specifically influences regional or global brain functional activity, and the corresponding fMRI responses.

Light-based or chemically-mediated cell-manipulations have made it possible to causally link the activity of focal neuronal populations with specific circuitual and behavioural outputs (Park and Carmel, 2016). When combined with *non-invasive* neuroimaging methods, cell-type specific manipulations can be used to map the functional substrates of endogenous modulatory transmission, without the confounding contribution of peripherally-elicited vasoactive or pharmacological effects. Towards this goal, here we describe the combined use of mouse cerebral-blood volume based fMRI (rCBV, Galbusera et al., 2017) and cell-type specific DREADD (Designed Receptors Exclusively Activated by Designed Drugs, Armbruster et al., 2007)) chemogenetics, an approach we term 'chemo-fMRI', to map the brainwide functional targets of sustained 5-HT stimulation.

To allow for stable and reproducible endogenous 5-HT stimulation across animals we generated a conditional knock-in mouse that we crossed with Pet1-Cre transgenic mice (Pelosi et al., 2014), endowing 5-HT specificity (Spencer and Deneris, 2017). This approach allowed us to remotely stimulate 5-HT-producing neurons during fMRI scans, with reduced inter-subject variability. Our results show that chemogenetic 5-HT stimulations do not affect global brain activity, but results in region specific activation of a set of primary target regions encompassing cortico-hippocampal, and midbrain structures, as well as components of the mesolimbic reward systems. Notably, pharmacological boosting of 5-HT level via systemic administration of the 5-HT reuptake inhibitor citalopram produced widespread fMRI *deactivation*, plausibly reflecting the mixed contribution of central and perivascular constrictive effects. Collectively, our results reveal a set of regional substrates that act as primary functional targets of endogenous serotonergic stimulation and establish causation between endogenous activation of 5-HT neurons and regional fMRI signals.

They also provide a novel framework for understanding 5-HT-dependent functions and interpreting data obtained from human fMRI studies of 5-HT modulating agents.

Results

hM3Dq-mediated modulation of serotonergic neurons

To enable stable pan-neuronal stimulation of 5-HT producing cells, we first generated a hM3Dq conditional knock-in mouse encompassing the integration of hM3Dq-mCherry double-floxed inverse open reading frame (DIO-hM3Dq) within the ROSA26 genomic locus (Fig. 1). In the designed mouse line, stable Cre-mediated somatic recombination is required for conditional transcriptional activation (CAG promoter-driven) of the hM3Dq gene, whose expression could be probed by the presence of in-frame-fused mCherry reporter (Fig. 1). To enable hM3Dq expression in 5-HT producing neurons, DIO-hM3Dq mice were crossed with the Pet1₂₁₀-Cre transgenic mouse line (Pelosi et al., 2014). Immunofluorescence analysis on double trans-heterozygous hM3Dq/Pet1-Cre mice revealed that hM3Dq is expressed in the vast majority (95.9%) of 5-HT producing neurons (Fig. 2A-D').

We next recorded the electrophysiological response induced by CNO administration in hM3Dq-expressing 5-HT neurons via whole-cell patch clamp recordings in the dorsal raphe nucleus (DRN). mCherry-positive neurons in hM3Dq/Pet1-Cre mice were robustly activated by CNO, resulting in sustained firing rates (Fig. 2E). We did not observe any CNO-induced firing rate alterations in any of the neighboring mCherry-negative neurons probed, or in 5-HT neurons in DIO-hM3Dq control mice (Fig. 2F-G).

Chemo-fMRI mapping of endogenous 5-HT neurotransmission

To control for possible off-target effects of CNO and its metabolites, we first performed a dose-response titration of the fMRI response produced by CNO in wild-type mice (Fig. S1). Intravenous CNO administration at doses of 1 and 2 mg/kg produced significant rCBV increases in most of the examined regions (Fig. S1, $p < 0.05$, corrected at $q = 0.05$). Upon intravenous dosing of CNO at 0.5

mg/kg the rCBV signal was qualitatively distinguishable from reference baseline signal only in hypothalamic and hippocampal areas, and no statistically significant alterations was detected in regional or voxelwise quantifications with respect to vehicle ($p>0.42$, $Z>1.6$ in voxelwise maps). Pharmacokinetic profiling of this dose (Fig. S1-C) revealed sustained plasma CNO exposure throughout the imaging time-window, plus the presence of low but detectable levels of clozapine. The observed peak exposure of clozapine (8 ± 6 ng/ml) is ~ 25 -fold lower than behaviorally-relevant plasma levels of this compound in rodents (Olsen et al., 2008), and below the range of values previously associated with detectable brain exposure (Volpicelli et al., 1993). Based on these assessments, we chose to perform subsequent chemogenetic-fMRI mapping using an i.v. dose of 0.5 mg/kg. As a further control for possible CNO/clozapine off-target effects, fMRI mapping and all the supporting experiments were performed and quantified by administering CNO to both hM3Dq/Pet1-Cre and control DIO-hM3Dq reference mice. CNO administration did not alter peripheral blood pressure at any of dose tested (Fig. S2)

Chemogenetic activation of 5-HT producing neurons elicited robust rCBV increases in several cortical and non-cortical substrates in hM3Dq/Pet1-Cre mice (Fig. 3, $Z>2$, cluster corrected $p=0.05$, Fig. S3). The elicited chemo-fMRI response encompassed parietal cortical and motor cortices, as well as posterior insular and temporal association regions, plus several subcortical substrates, including hippocampal areas, the hypothalamus, the dorsal raphe and cerebellum. A prominent involvement of ventral tegmental area and its mesolimbic terminals in the nucleus accumbens was also apparent.

To probe a neural origin of hM3Dq-mediated fMRI response, we performed local field potential (LFP) measurements in the dorsal hippocampus of halothane-anesthetized animals (Galbusera et al., 2017). CNO administration (0.5 mg/kg i.v.) produced significant LFP power increases in the theta ($F_{1,22}=110.2$ $p<0.001$) and gamma bands ($F_{1,22}=239.4$ $p<0.001$) in

hM3Dq/Pet1-Cre, but not in DIO-M3Dq control animals (Fig. S4). To rule out an interaction between the anesthesia used for fMRI and 5-HT chemogenetic manipulations, we carried out c-Fos immunofluorescence mapping in unanesthetized mice upon intraperitoneal administration of 2 mg/kg of CNO (see dose selection in Supplemental Experimental Procedures). This dosing strategy does not elicit substantial fMRI signal alterations (Fig. S5, $p > 0.26$ all regions). We observed robust and recognizable increases in c-Fos positive neurons in many regional substrates identified with fMRI, including the nucleus accumbens, hippocampus, anterior thalamus, hypothalamic nuclei and raphe nuclei (Fig. S6 A-E, $p < 0.05$, all regions, $q = 0.05$). No inter-group differences were observed in somatosensory cortex (Fig. S6 A-E), while no detectable c-Fos reactivity was observed in the cerebellum in either CNO-treated group (data not shown). The same dose of CNO (2 mg/kg i.p.) elicited significant release of extracellular serotonin in hM3Dq/Pet1-Cre, but not in DIO-M3Dq control animals as assessed with hippocampal microdialysis in unanesthetized animals (Fig S6-F, $F_{1,10} = 7.76$, $p = 0.02$).

Systemic 5-HT reuptake inhibition produces fMRI deactivation

An underlying assumption of our work is that the signals elicited by CNO in hM3Dq/Pet1-Cre mice primarily reflect central 5-HT neuronal stimulation, which in turns elicits rCBV changes via neurovascular and neurometabolic coupling. By contrast, fMRI mapping of systemically-administered 5-HT ligands may be contaminated or masked by direct stimulation of endothelial 5-HT receptors, which produces vasoconstrictive responses (Cohen et al., 1996). To compare the effect of endogenous versus systemic pharmacological 5-HT stimulation, we carried out fMRI mapping upon administration of the selective 5-HT reuptake inhibitor citalopram (5-10 mg/kg), a drug leading to increased central and circulating 5-HT levels (Blardi et al., 2005). Interestingly, citalopram (10mg/kg i.v.) produced widespread foci of rCBV signal decrease in a widespread set of cortical and subcortical regions, as seen with voxelwise mapping (Fig. S7, $Z > 1.8$, cluster corrected

$p=0.05$). Although the effect was widely distributed, the deactivation was particularly prominent in the prefrontal cortex (Fig. 4B, Fig. S7). Citalopram administration was not associated with appreciable blood pressure alteration at any of the doses tested (Fig. S2).

Discussion

Serotonin is an archetypical neuromodulatory monoamine characterized by broad and far-ranging modulatory properties. Despite extensive research, the macroscale functional substrates endogenously modulated by 5-HT in the intact brain remain elusive. By using chemo-fMRI, we describe the primary brainwide targets of sustained serotonergic stimulation, and establish causation between endogenous activation of 5-HT neurons and regional fMRI signals. Our results provide a novel framework for understanding 5-HT-dependent function and interpreting data obtained from human fMRI studies of 5-HT modulatory agents.

While the density of 5-HT ascending projection is highly variable across neuroanatomical regions, virtually no area in the central nervous system is devoid of 5-HT innervation (Maddaloni et al., 2017). Our observation of region-specific responses in spite of the use of drug-like pan-serotonergic stimulation provides evidence that endogenous 5-HT neurotransmission engages a set of neuroanatomical targets that serve as primary, fast-responding effectors of sustained release of this neurotransmitter. This notion is consistent with a role of 5-HT as a mediator of arousal (Lee and Dan, 2012), and species-normative consummatory behaviours that strongly engage evolutionary-ancient ventro-limbic substrates (Takahashi et al., 2012, Liu et al., 2014). The presence of parieto-cortical activation is in keeping with the result of metabolic and cerebral blood flow mapping upon electrical or chemical stimulation of raphe regions (Cohen et al., 1996, Underwood et al., 1995). While the robust activation of hippocampal, hypothalamic, and midbrain areas is consistent with the especially dense 5-HT innervation of these areas, qualitative comparisons with prior fiber or 5-HT terminal density quantifications (Willoughby and Blessing, 1987, Maddaloni et al., 2017) do not support a regional relationship between rCBV activation and 5-HT innervation density. Different 5-HT signaling properties, such as a differential contribution of wiring and volume transmission (Descarries and Mechawar, 2000), as well as regional combinations of receptor subtypes

characterized by different transductional pathways or cellular distribution may underlie the selective functional engagement observed with endogenous 5-HT stimulation. Importantly, our mapping provides functional evidence that serotonergic activation can also modulate the activity of mesolimbic dopaminergic areas such as the nucleus accumbens. This finding underscores a functional interplay between these two key modulatory systems, and supports the emerging view of a role of 5-HT as a possible modulator of reward processing and mesolimbic dopaminergic substrates (Li et al., 2016, Luo et al., 2015). A mechanistic contribution of promiscuous monoaminergic transport could also play a role in the mapped activation, as suggested by recent molecular imaging studies (Hai et al., 2016, Zhou et al., 2005).

Interestingly, recent mapping of chemogenetically-stimulated neurons via 2-fluoro-dexoy-glucose PET did not highlight cortico-hippocampal modulation of brain activity, but revealed small foci of reduced metabolism in thalamic areas (Urban et al., 2016). Several experimental factors could account for these discrepant results, including the use of deep anaesthesia vs. light sedation, and the possible contribution of unspecific effects of CNO, given that Urban et al., did not employ a CNO-treated group as a baseline reference for brain mapping. This aspect is of especial importance in the light of a recent report pointing at a possible role of converted clozapine as primary effector of DREADD-induced manipulations (Gomez et al., 2017). Our pharmacokinetic data are consistent with this view, showing that CNO can be converted to clozapine *in vivo*. However, several lines of evidence argue against a significant off-target contribution of converted clozapine to our mapping. First, our chemo-fMRI mapping was performed at CNO doses that negligibly affect fMRI signals. Second, we have quantified and described all chemogenetic responses with respect to a CNO-treated DIO-hMD3q control group of animals. Third, *in vivo* LFP recordings and microdialysis studies provide evidence of neural responses and extracellular 5-HT release in hM3Dq/Pet1-Cre, but not in DIO-M3Dq control animals. Finally, consistent with the notion of “subthreshold clozapine exposure”

(Gomez et al., 2017), the measured peak clozapine concentration is \sim 25-fold lower the exposure required to obtain behaviourally-relevant responses in rodents (Olsen et al., 2008), and below the range of values previously associated with detectable brain exposure in pharmacokinetic studies (Volpicelli et al., 1993). Taken together, these findings strongly argue against a contribution of unspecific clozapine-related effects to the signals mapped with our approach.

Our results provide a novel reference framework for the interpretation of fMRI imaging studies employing 5-HT-targeting agents. In this respect, the divergent functional effects observed with chemogenetic stimulation and 5-HT reuptake inhibition are especially relevant, as they suggest that endogenous versus systemic 5-HT level boosting can lead to opposing hemodynamic responses, a factor that needs to be taken into account when hemodynamic readouts are used as surrogates for 5-HT induced neural manipulations. 5-HT is a key mediator of central and peripheral vasoactivity, with predominant evidence of a vasoconstrictive action via 5-HT_{1A}, 5-HT_{1B} and 5-HT_{2A} receptors located in brain and peripheral vascular cells (reviewed by Cohen et al., 1996). Because 5-HT reuptake inhibition rapidly increases circulating levels of this neurotransmitter (Blardi et al., 2005, Zolkowska et al., 2008), and systemic 5-HT administration produces endothelial vasoconstriction (Toda and Fujita, 1973, Cohen et al., 1996), citalopram-induced rCBV decreases could reflect a contribution of direct vasoactive effect of circulating 5-HT on cerebral vasculature. Non-vascular mechanisms could also be involved in this effect, such as a possible engagement of different receptorial populations as a function of 5-HT release site, a hypothesis consistent with the wide variety in the anatomical and cellular distribution patterns exhibited by the 5-HT receptors subtypes so far identified (Lesch and Waider, 2012).

While reduced cerebral blood flow in humans and rats has been reported upon citalopram administration (McBean et al., 1999, Geday et al., 2005), prior blood oxygen level-dependent (BOLD) fMRI mapping of citalopram in rats revealed increased cortical responses (Sekar et al.,

2011). A number of methodological discrepancies could account for this result, the use of deeper anesthesia levels by Sekar et al., as well as the use of BOLD fMRI, as opposed to rCBV like in the present work, being the two most notable ones. In this respect, it should be emphasized that CBV is a direct and reliable indicator of microvascular activity that appears to be more directly related to underlying neuronal activity than BOLD fMRI (Schridde et al., 2008). Further opto- or chemogenetic fMRI mapping of 5-HT function employing BOLD fMRI could help conciliate these experimental discrepancies.

The results of our microdialysis and LFP recordings, plus the observation of c-Fos induction in many regions exhibiting significant chemo-fMRI activation argue against a significant interference of anesthesia on our functional mapping, and support a neural origin of the mapped signals. Not surprisingly, discrepancies between imaging and c-Fos mapping were noted, for example in cortical regions or in the cerebellum. Such differences are not surprising given the diverse neurophysiological mechanisms underlying these two experimental readouts, and previous evidence showing that c-Fos induction does not always correspond to activation shown by metabolic or hemodynamic-based brain mapping (Stark et al., 2006, Gozzi et al., 2012, Gass et al., 1997). Indeed, hemodynamic responses are generally thought to reflect local synaptic input (Logothetis et al., 2001), whereas the c-Fos protein induction is an indirect marker of cellular activation that is not elicited in all CNS cell and that can be affected by the behavioral state of the animal (Cirelli and Tononi, 2000).

From a methodological standpoint, this work paves the way to the combined use of chemogenetic and fMRI to unravel the large-scale substrates modulated by pan-neuronal populations in the living mouse brain. Our approach follows analogous attempts to combine chemogenetics with non-invasive mouse brain imaging (Urban et al., 2016). Our data demonstrate that properly-controlled chemogenetic-fMRI studies can elicit large and sustained functional

responses that exhibit neuronal specificity, and can be employed to obtain to non-invasively map the brainwide effect of regional neural manipulations. This approach crucially complements current opto-fMRI simulations (Lee et al., 2010) by permitting brainwide functional mapping without the need of invasive cranial probes, and devoid of the confounding contribution of heat-induced vasodilation in anesthetized animals (Rungta et al., 2017). As such, chemo-fMRI appears to be optimally suited to the investigation of drug-like sustained modulatory stimulation/inhibition and for the deconstruction or manipulation of steady-state network activity via fMRI connectivity mapping (Gozzi and Schwarz, 2015). While here employed to study pan-neuronal 5-HT modulation, this approach can be straightforwardly expanded to manipulate focal circuits and neuronal ensembles via intersectional genetics or retrograde viral vectors.

In conclusion, we describe the use of chemo-fMRI to map the brainwide substrates of modulatory transmission in the intact mammalian brain. We show that chemogenetic stimulation of endogenous serotonin neurons results in regionally-specific activation of a set of cortical and subcortical targets that serve as primary functional mediators of sustained endogenous 5-HT transmission. We also show that endogenous activation of serotonergic neurons and systemic 5-HT reuptake inhibition can produce opposing hemodynamic effects. Our findings provide a novel framework for understanding serotonin dependent functions, and interpreting data obtained from human fMRI studies of serotonin modulating agents.

Experimental Procedures

Full-length experimental procedures can be found in Supplemental Information.

Mouse line generation. The hM3Dq sequence fused with mCherry was isolated by a pAAV-hSyn-DIO-hM3Dq construct (a kind gift From Dr. Bryan Roth) and inversely cloned into the ROSA26 locus (Krashes et al., 2011). PvuI-linearized pROSA26-1^{Sor}-LA-CAG-DIO-hM3Dq-NEO-RA-DTa was electroporated in E14Tg2a.4 embryonic stem cells (ESCs). To enable the expression of hM3Dq in 5-HT producing neurons, mice were then crossed with Pet1₂₁₀-Cre mice (Pelosi et al., 2014).

Immunohistochemical analyses and cell counting. Free floating sections were incubated at 4°C overnight with rabbit anti-RFP (ab62341, Abcam, 1:500) and goat anti-Tph2 (ab121020, Abcam, 1:800). Sections were then incubated with donkey anti-rabbit (Rhodamine Red, Invitrogen, 1:500) and anti-goat (Alexa Fluor 488, Invitrogen, 1:500). c-Fos mapping was carried out as using a goat anti-cFos (SC-52-G, Santa Cruz Biotechnology, 1:1000) in a 5% horse inactivated serum solution. Sections were then incubated overnight at 4°C with donkey anti-goat (Alexa Fluor 488, Invitrogen, 1:500).

Brain Slice Electrophysiology. Brains of hM3Dq/Pet1-Cre were sectioned to obtain 300 µm coronal slices encompassing the dorsal raphe nucleus. Whole-cell patch clamp experiments were performed using borosilicate electrodes to patch DRN cells. After 5 minutes of stable baseline, CNO (10 µM) was bath applied for 10 minutes while recording changes in membrane potential.

fMRI. Animal preparation for fMRI has been previously described (Ferrari et al., 2012). All drugs were administered intravenously. fMRI data were acquired on a 7T Pharmascan using intrapulmonary halothane anaesthesia (0.8%) and analyzed as previously described (Galbusera et al., 2017). Images were sensitized to reflect alterations in rCBV using Molday Ion, Biopal, USA.

In vivo electrophysiology

LFP recordings were performed on a separate cohort of halothane anaesthetised DIO/hM3Dq or hM3Dq/Pet1-Cre mice, using the same animal preparation and anesthesia employed for fMRI. Surgery, recordings and data analyses were carried out as previously described (Galbusera et al., 2017).

***In vivo* brain microdialysis**

Microdialysis experiments were performed as recently described (Managò et al., 2016). Mice were implanted with concentric dialysis probes in the dorsal hippocampus. Microdialysis experiments were performed upon intraperitoneal administration of CNO (2 mg/kg). Dialysate samples (20µL) were analyzed using HPLC apparatus and a colorimetric electrochemical detector to quantify 5-HT.

Pharmacokinetic measurements

Blood samples (100 µl) were collected from C57BL/6J mice at different time point (15-30-60 min), Plasma levels of clozapine-N-oxide, clozapine and dimethyl-clozapine were monitored on a ACQUITY UPLC/MS TQD system consisting of a TQD (Triple Quadrupole Detector) mass spectrometer equipped with an electrospray ionization interface (Olsen et al., 2008). Compounds were quantified by monitoring their MRM peak areas.

Acknowledgements

This work was supported by Italian Ministry of Education, University and Research (MIUR) (Prin 2008, 200894SYW2), Toscana Life Sciences Foundation (Orphan_0108 program) and Norwegian Research Council to MP. AGo acknowledges funding from the Simons Foundation (SFARI 314688 and 400101) and Brain and Behaviour Foundation (2017 NARSAD independent Investigator Grant). SM was supported by Regional Program and European Social Fund. We thank Bryan Roth for generously supplying hM3Dq and hM3Di cDNA, Carola Canella for helping with figure generation, C. Valente for his excellent technical assistance and members of our laboratories for valuable discussions and comments on the manuscript.

Author contribution

AGo and MP conceived the study. AGi generated the transgenic line, carried out fMRI studies and analysed the data with input from AGo, AGa, GM, SM and AMD. RT and MG carried out in slice electrophysiological measurements. AGa, SL, FT and GMR carried out and analyzed *in vivo* electrophysiological recordings. AA and SMB performed pharmacokinetic studies. MADL, MM and GM performed in vivo microdialysis measurements. AGo wrote the manuscript.




Figure 1

Generation of hM3Dq conditional knock-in mouse line. Targeted integration of the hM3Dq construct in the ROSA26 genomic locus. (A, top to bottom) Wild-type organization of ROSA26 mouse genomic locus; hM3Dq targeting vector: green (LoxP) and blue (Lox2722) arrowheads indicate the location of Lox sites, yellow circles indicate FRT sites; transcriptionally inactive DIO-hM3Dq allele; transcriptionally active hM3Dq allele (B) Southern blot analysis of genomic DNA extracted from embryonic stem cells clones after *HindIII* digestion (hM3Dq allele=6,7 kb; wild-type allele=4,4 kb). (C) PCR amplification of ROSA26 locus from DNA extracted from a wild-type (3), two mutant mice (1 and 4) and two heterozygous (2 and 5) DIO-hM3Dq mice.





Figure 2

hM3Dq expression in 5-HT neurons and electrophysiological validation. (A-C) Double immunohistochemical assay showing (A) Tph2 and (B) mCherry expression, and (C) merged channels in medial and dorsal raphe nucleus (MRN and DRN, respectively) of hM3Dq/Pet1-Cre mice (n=4). High power magnification highlighting Tph2/mCherry co-localization (A',B',C') in the DRN lateral wings and in MRN (A'',B'',C''). (D) Quantification of hM3Dq-expressing 5-HT neurons. (E) CNO

application (5 μ M, purple bar) in DRN brain slices from hM3Dq/Pet1-Cre mice triggered firing activity in mCherry(+) 5-HT neurons (discharge rate 0.19 ± 0.03 Hz, $p = 0.003$), identified by their electrophysiological properties (inset). CNO did not elicit activity in mCherry(-) cells (F), or in DIO-hM3Dq control cells. (E-G) Left, image of recorded cells; middle, sample traces of recorded cell membrane potential; right, box plot summary of changes in discharge rate in response to CNO application. Scale bar, 380 μ m (A-C), 150 μ m (A'-C'').




Figure 3

fMRI response to chemogenetic stimulation of serotonergic neurons. fMRI activation produced by intravenous CNO administration (0.5 mg/kg, i.v.) in hM3Dq/Pet1-Cre mice (n=20) vs CNO-treated DIO-hM3Dq controls (n=14). (A) Anatomical distribution of the brain regions activated in hM3Dq/Pet1-Cre mice ($Z > 2$, cluster corrected at $p = 0.05$) (B) Illustrative fMRI timecourse in the hippocampus, CNO was administered at time 0 (means \pm SEM). (C) rCBV quantification in representative volumes of interest (means \pm SEM, * $p < 0.05$, ** $p < 0.01$, corrected at $q = 0.05$). Hp: hippocampus; NAc: nucleus accumbens; SS : somatosensory cortex; Th: thalamus; Hyp: hypothalamus; DRN: dorsal raphe nucleus; Cb: cerebellum, mPFC: prefrontal cortex.




Figure 4

Brainwide fMRI response to systemic citalopram administration. (A) Anatomical distribution of the brain regions deactivated by citalopram (10 mg/kg) (n=7) vs. vehicle (z>1.8, cluster correction p=0.05) (n=10). (B) Illustrative fMRI timecourse in the prefrontal cortex (means ± SEM), citalopram was administered at time 0. (C) rCBV quantification in representative volumes of interest (means ± SEM, *p<0.05, **p< 0.01, corrected at q=0.05). Hp: hippocampus; NAc: nucleus accumbens; SS: somatosensory cortex; Th: thalamus; Hyp: hypothalamus; DRN: dorsal raphe nucleus; Cb: cerebellum, mPFC: prefrontal cortex; Cg: cingulate cortex; V1: Visual cortex; Ent: entorhinal cortex.

References

- ANDERSON, I. M., MCKIE, S., ELLIOTT, R., WILLIAMS, S. R. & DEAKIN, J. F. W. 2008. Assessing human 5-HT function in vivo with pharmacMRI. *Neuropharmacology*, 55, 1029-1037.
- ARMBRUSTER, B. N., LI, X., PAUSCH, M. H., HERLITZE, S. & ROTH, B. L. 2007. Evolving the lock to fit the key to create a family of G protein-coupled receptors potently activated by an inert ligand. *Proceedings of the National Academy of Sciences*, 104, 5163-5168.
- BLARDI, P., DE LALLA, A., URSO, R., AUTERI, A., DELL'ERBA, A., BOSSINI, L. & CASTROGIOVANNI, P. 2005. Activity of citalopram on adenosine and serotonin circulating levels in depressed patients. *J Clin Psychopharmacol*, 25, 262-6.
- CIRELLI, C. & TONONI, G. 2000. On the functional significance of c-fos induction during the sleep-waking cycle. *Sleep*, 23, 453-69.
- COHEN, Z., BONVENTO, G., LACOMBE, P. & HAMEL, E. 1996. Serotonin In The Regulation Of Brain Microcirculation. *Progress in Neurobiology*, 50, 335-362.
- DESCARRIES, L. & MECHAWAR, N. 2000. Ultrastructural evidence for diffuse transmission by monoamine and acetylcholine neurons of the central nervous system. *Progress in Brain Research*. Elsevier.
- FERRARI, L., TURRINI, G., CRESTAN, V., BERTANI, S., CRISTOFORI, P., BIFONE, A. & GOZZI, A. 2012. A robust experimental protocol for pharmacological fMRI in rats and mice. *Journal of Neuroscience Methods*, 204, 9-18.
- GALBUSERA, A., DE FELICE, A., GIRARDI, S., BASSETTO, G., MASCHIETTO, M., NISHIMORI, K., CHINI, B., PAPALETTO, F., VASSANELLI, S. & GOZZI, A. 2017. Intranasal Oxytocin and Vasopressin Modulate Divergent Brainwide Functional Substrates. *Neuropsychopharmacology*.

- GASS, P., BRUEHL, C., HERDEGEN, T., KIESSLING, M., LUTZENBURG, M. & WITTE, O. W. 1997. Induction of FOS and JUN proteins during focal epilepsy: congruences with and differences to [14C]deoxyglucose metabolism. *Brain Res Mol Brain Res*, 46, 177-84.
- GEDAY, J., HERMANSEN, F., ROSENBERG, R. & SMITH, D. F. 2005. Serotonin modulation of cerebral blood flow measured with positron emission tomography (PET) in humans. *Synapse*, 55, 224-229.
- GOMEZ, J. L., BONAVENTURA, J., LESNIAK, W., MATHEWS, W. B., SYSA-SHAH, P., RODRIGUEZ, L. A., ELLIS, R. J., RICHIE, C. T., HARVEY, B. K., DANNALS, R. F., POMPER, M. G., BONCI, A. & MICHAELIDES, M. 2017. Chemogenetics revealed: DREADD occupancy and activation via converted clozapine. *Science*, 357, 503-507.
- GOZZI, A., COLAVITO, V., SEKE ETET, P. F., MONTANARI, D., FIORINI, S., TAMBALO, S., BIFONE, A., ZUCCONI, G. G. & BENTIVOGLIO, M. 2012. Modulation of Fronto-Cortical Activity by Modafinil: A Functional Imaging and Fos Study in the Rat. *Neuropsychopharmacology*, 37, 822-837.
- GOZZI, A. & SCHWARZ, A. J. 2015. Large-scale functional connectivity networks in the rodent brain. *NeuroImage*.
- HAI, A., CAI, LILI X., LEE, T., LELYVELD, VICTOR S. & JASANOFF, A. 2016. Molecular fMRI of Serotonin Transport. *Neuron*, 92, 754-765.
- KLOMP, A., TREMOLEDA, J. L., SCHRANTEE, A., GSELL, W. & RENEMAN, L. 2012. The use of pharmacological-challenge fMRI in pre-clinical research: application to the 5-HT system. *J Vis Exp*.
- KRASHES, M. J., KODA, S., YE, C., ROGAN, S. C., ADAMS, A. C., CUSHER, D. S., MARATOS-FLIER, E., ROTH, B. L. & LOWELL, B. B. 2011. Rapid, reversible activation of AgRP neurons drives feeding behavior in mice. *The Journal of Clinical Investigation*, 121, 1424-1428.

- LEE, J. H., DURAND, R., GRADINARU, V., ZHANG, F., GOSHEN, I., KIM, D. S., FENNO, L. E., RAMAKRISHNAN, C. & DEISSEROTH, K. 2010. Global and local fMRI signals driven by neurons defined optogenetically by type and wiring. *Nature*, 465, 788-792.
- LEE, S. H. & DAN, Y. 2012. Neuromodulation of brain states. *Neuron*, 76, 209-222.
- LESCH, K.-P. & WAIDER, J. 2012. Serotonin in the Modulation of Neural Plasticity and Networks: Implications for Neurodevelopmental Disorders. *Neuron*, 76, 175-191.
- LI, Y., ZHONG, W., WANG, D., FENG, Q., LIU, Z., ZHOU, J., JIA, C., HU, F., ZENG, J., GUO, Q., FU, L. & LUO, M. 2016. Serotonin neurons in the dorsal raphe nucleus encode reward signals. *Nature Communications*, 7, 10503.
- LIU, Z., ZHOU, J., LI, Y., HU, F., LU, Y., MA, M., FENG, Q., ZHANG, J.-E., WANG, D., ZENG, J., BAO, J., KIM, J.-Y., CHEN, Z.-F., EL MESTIKAWY, S. & LUO, M. 2014. Dorsal Raphe Neurons Signal Reward through 5-HT and Glutamate. *Neuron*, 81, 1360-1374.
- LOGOTHETIS, N. K., PAULS, J., AUGATH, M., TRINATH, T. & OELTERMANN, A. 2001. Neurophysiological investigation of the basis of the fMRI signal. *Nature*, 412, 150-157.
- LUO, M., ZHOU, J. & LIU, Z. 2015. Reward processing by the dorsal raphe nucleus: 5-HT and beyond. *Learn Mem*, 22, 452-60.
- MADDALONI, G., BERTERO, A., PRATELLI, M., BARSOTTI, N., BOONSTRA, A., GIORGI, A., MIGLIARINI, S. & PASQUALETTI, M. 2017. Development of Serotonergic Fibers in the Post-Natal Mouse Brain. *Frontiers in Cellular Neuroscience*, 11.
- MANAGÒ, F., MEREU, M., MASTWAL, S., MASTROGIACOMO, R., SCHEGGIA, D., EMANUELE, M., DE LUCA, MARIA A., WEINBERGER, DANIEL R., WANG, KUAN H. & PAPALEO, F. 2016. Genetic Disruption of Arc/Arg3.1 in Mice Causes Alterations in Dopamine and Neurobehavioral Phenotypes Related to Schizophrenia. *Cell Reports*, 16, 2116-2128.

- MARTIN, C. & SIBSON, N. R. 2008. Pharmacological MRI in animal models: a useful tool for 5-HT research? *Neuropharmacology*, 55, 1038-47.
- MCBEAN, D. E., RITCHIE, I. M., OLVERMAN, H. J. & KELLY, P. A. T. 1999. Effects of the specific serotonin reuptake inhibitor, citalopram, upon local cerebral blood flow and glucose utilisation in the rat. *Brain Research*, 847, 80-84.
- OFEK, K., SCHOKNECHT, K., MELAMED-BOOK, N., HEINEMANN, U., FRIEDMAN, A. & SOREQ, H. 2012. Fluoxetine induces vasodilatation of cerebral arterioles by co-modulating NO/muscarinic signalling. *Journal of Cellular and Molecular Medicine*, 16, 2736-2744.
- OLSEN, C. K., BRENNUM, L. T. & KREILGAARD, M. 2008. Using pharmacokinetic–pharmacodynamic modelling as a tool for prediction of therapeutic effective plasma levels of antipsychotics. *European journal of pharmacology*, 584, 318-327.
- PARK, H. G. & CARMEL, J. B. 2016. Selective Manipulation of Neural Circuits. *Neurotherapeutics*, 13, 311-324.
- PELOSI, B., MIGLIARINI, S., PACINI, G., PRATELLI, M. & PASQUALETTI, M. 2014. Generation of Pet1210Cre Transgenic Mouse Line Reveals Non-Serotonergic Expression Domains of Pet1 Both in CNS and Periphery. *PLoS ONE*, 9, e104318.
- RUNGTA, R. L., OSMANSKI, B.-F., BOIDO, D., TANTER, M. & CHARPAK, S. 2017. Light controls cerebral blood flow in naive animals. *Nature Communications*, 8, 14191.
- SCHRIDDE, U., KHUBCHANDANI, M., MOTELow, J. E., SANGANAHALLI, B. G., HYDER, F. & BLUMENFELD, H. 2008. Negative BOLD with Large Increases in Neuronal Activity. *Cerebral Cortex*, 18, 1814-1827.
- SEKAR, S., VERHOYE, M., VAN AUDEKERKE, J., VANHOUTTE, G., LOWE, A. S., BLAMIRE, A. M., STECKLER, T., VAN DER LINDEN, A. & SHOAIB, M. 2011. Neuroadaptive responses to

citalopram in rats using pharmacological magnetic resonance imaging.

Psychopharmacology, 213, 521-531.

SPENCER, W. C. & DENERIS, E. S. 2017. Regulatory Mechanisms Controlling Maturation of Serotonin Neuron Identity and Function. *Frontiers in Cellular Neuroscience*, 11.

STARK, J. A., DAVIES, K. E., WILLIAMS, S. R. & LUCKMAN, S. M. 2006. Functional magnetic resonance imaging and c-Fos mapping in rats following an anorectic dose of m-chlorophenylpiperazine. *NeuroImage*, 31, 1228-1237.

TAKAHASHI, A., QUADROS, I. M., DE ALMEIDA, R. M. M. & MICZEK, K. A. 2012. Behavioral and Pharmacogenetics of Aggressive Behavior. In: CRYAN, J. F. & REIF, A. (eds.) *Behavioral Neurogenetics*. Berlin, Heidelberg: Springer Berlin Heidelberg.

TODA, N. & FUJITA, Y. 1973. Responsiveness of Isolated Cerebral and Peripheral Arteries to Serotonin, Norepinephrine, and Transmural Electrical Stimulation. *Circulation Research*, 33, 98-104.

UNDERWOOD, M. D., BAKALIAN, M. J., ARANGO, V. & JOHN MANN, J. 1995. Effect of chemical stimulation of the dorsal raphe nucleus on cerebral blood flow in rat. *Neuroscience Letters*, 199, 228-230.

URBAN, D. J., ZHU, H., MARCINKIEWCZ, C. A., MICHAELIDES, M., OSHIBUCHI, H., RHEA, D., ARYAL, D. K., FARRELL, M. S., LOWERY-GIONTA, E., OLSEN, R. H., WETSEL, W. C., KASH, T. L., HURD, Y. L., TECOTT, L. H. & ROTH, B. L. 2016. Elucidation of The Behavioral Program and Neuronal Network Encoded by Dorsal Raphe Serotonergic Neurons. *Neuropsychopharmacology*, 41, 1404-15.

VOLPICELLI, S. A., HUSTON-LYONS, D. & COHEN, B. M. 1993. Tissue concentrations of clozapine and its metabolites in the rat. *Neuropsychopharmacology*, 9, 117-124.

WILLOUGHBY, J. O. & BLESSING, W. W. 1987. Origin of serotonin innervation of the arcuate and ventromedial hypothalamic region. *Brain Research*, 418, 170-173.

ZHOU, F.-M., LIANG, Y., SALAS, R., ZHANG, L., DE BIASI, M. & DANI, J. A. 2005. Corelease of Dopamine and Serotonin from Striatal Dopamine Terminals. *Neuron*, 46, 65-74.

ZOLKOWSKA, D., BAUMANN, M. H. & ROTHMAN, R. B. 2008. Chronic fenfluramine administration increases plasma serotonin (5-hydroxytryptamine) to nontoxic levels. *J Pharmacol Exp Ther*, 324, 791-7.

Supplemental Information Inventory

Supplemental data items

Figure S1, CNO dose response, related to Figure 2.

Figure S2, Temporal profile of mean arterial blood pressure, related to Figure 3 and 4.

Figure S3, rCBV timecourse produced by chemogenetic stimulation of 5-HT neurons, related to figure 3.

Figure S4, Hippocampal LFP recordings, related to Figure 3

Figure S5, rCBV response to intraperitoneal CNO in wild-type mice, related to Figure 3

Figure S6, c-Fos induction and extracellular 5-HT release produced by hM3Dq activation of 5-HT neurons, related to Figure 3

Figure S7, rCBV timecourse produced by intravenous citalopram administration in wild-type mice, related to Figure 4.

Supplemental Experimental Procedures

Supplemental figures




Figure S1, CNO dose response, related to Figure 3

(A) rCBV timecourse produced by intravenous CNO administration in wild-type mice. CNO was administered intravenously at doses of 0.5 (n=6), 1 (n=4) or 2 mg/kg (n=5). rCBV timecourses are depicted in representative volumes of interest (VOIs) as means \pm SEM. CNO or vehicle were administered at time 0; (B) Quantification of the mean rCBV response elicited by CNO in representative VOIs. Data are shown as mean \pm standard error of the mean. * $p < 0.05$, ** $p < 0.01$, Student t test, false discovery rate correction $q = 0.05$. The anatomical location of volumes of interest is depicted in Figure S5 (panel B). Hp: hippocampus; mPFC: prefrontal cortex; DRN: dorsal raphe nucleus; NAc: nucleus accumbens; Th: thalamus; Hyp: hypothalamus; SS: somatosensory cortex; Cb: cerebellum. (C) Plasma exposure of CNO and its metabolites clozapine and N-Desmethylclozapine (NDMC) upon intravenous administration of the dose employed in fMRI studies (0.5 mg/kg).




Figure S2, Temporal profile of mean arterial blood pressure, related to Figures 3 and 4.

Temporal profile of mean arterial blood pressure (MABP). (Top) MABP timecourse upon vehicle (n = 5) or CNO administration at doses of 0.5 (n=6), 1 (n=4) or 2 mg/kg i.v. (n=5). (Middle) MABP upon CNO administration (0.5 mg/kg i.v.) to hM3Dq/Pet1-Cre (n=20) or DIO-hM3Dq (n=14) control subjects. MABP timecourse (Bottom) upon vehicle (n=10) or citalopram administration at dose of 5 (n=8) or 10 mg/kg i.v. (n=7) to wild type mice. Data are plotted as means \pm SD. Drugs and vehicle were administered at time 0.




Figure S3, rCBV timecourse produced by chemogenetic stimulation of 5-HT neurons, related to figure 3.

fMRI timeseries upon intravenous CNO administration (0.5 mg/kg) to hM3Dq/Pet1-Cre (n=20) and DIO-hM3Dq controls (n=14) mice in representative volumes of interest. The anatomical location of volumes of interest is depicted in Figure S5 (panel B). Data are plotted as means \pm SEM. Hp: hippocampus; mPFC: prefrontal cortex; DRN: dorsal raphe nucleus; NAc: nucleus accumbens; Th: thalamus; Hyp: hypothalamus; SS: somatosensory cortex; Cb: cerebellum.




Figure S4, Hippocampal LFP recordings, related to Figure 3

Time course of absolute theta and gamma power in the hippocampus of hM3Dq/Pet1-Cre (n=5) and DIO-hM3Dq control (n=5) mice upon intravenous CNO administration (0.5 mg/kg). Recordings were carried out under halothane sedation to replicate the same experimental conditions of fMRI. Bars indicate the standard error of the mean of individual data points. Linear regressions (solid lines) show a significant difference in absolute power change across the whole time window (***) $p < 0.001$.




Figure S5, rCBV response to intraperitoneal CNO in wild-type mice, related to Figure 3

(A) rCBV timecourse produced by intraperitoneal CNO administration in wild-type mice (2 mg/kg, $n = 6$, vehicle, $n = 6$). rCBV timecourses are depicted in representative volumes of interest (VOIs) as means \pm SEM. CNO or vehicle were administered at time 0; (B) Volumes of interest used for rCBV quantification. Hp: hippocampus; mPFC: prefrontal cortex; DRN: dorsal raphe nucleus; NAc: nucleus accumbens; Hyp: hypothalamus; SS: somatosensory cortex. (C) Quantification of the mean rCBV response elicited by CNO in representative VOIs. Data are shown as mean \pm standard error of the mean. No comparison was statistically significant ($p > 0.26$ all VOIs, Student t test).




Figure S6, c-Fos induction and extracellular 5-HT release produced by hM3Dq activation of 5-HT neurons, related to Figure 3

Regional c-Fos immunofluorescence in the brain of hM3Dq/Pet1-Cre mice (n=5) and control (DIO-hM3Dq, n=5) subjects treated with CNO (2 mg/kg, i.p.). (A-E) c-Fos induction produced by hM3Dq-mediated activation of 5-HT neurons. (A-D) Distribution of c-Fos-positive (green) cells (A, A') in the hippocampus and (B, B') nucleus accumbens of hM3Dq/Pet1-Cre and control mice (C, C', D, D'). (E) Quantification of c-Fos-positive cells in the regions of interest (*p<0.05, **p<0.01, Student t test, false discovery rate correction q=0.05). CA1: Cornu Ammonis 1; DG: dentate gyrus; AcbS: nucleus accumbens shell; ACo: anterior commissure; Hp: hippocampus; NAc: nucleus accumbens; SS: somatosensory cortex; Th: thalamus; Hyp: hypothalamus; DRN: dorsal raphe nucleus; Cb: cerebellum; mPFC: prefrontal cortex. Scale bar, Scale bar, 250 μ m (A-D), 60 μ m (A'-D'). (F) Extracellular serotonin release in dorsal hippocampus of hM3Dq/Pet1-Cre (n=6) and control DIO-hM3Dq mice (n=6) upon intraperitoneal administration of CNO (2 mg/kg i.p., injection at time 0, means \pm SEM) in freely-behaving animals (*p<0.05, two-way ANOVA).




Figure S7, rCBV timecourse produced by intravenous citalopram administration in wild-type mice, related to Figure 4.

rCBV timecourse produced by intravenous citalopram administration in wild-type mice. Citalopram was administered at a dose of 5 (n=8) or 10 mg/kg i.v. (n=7) at time 0. The anatomical location of volumes of interest is depicted in Figure S5 (panel B). Data are shown as means \pm SEM. Hp: hippocampus; mPFC: prefrontal cortex; DRN: dorsal raphe nucleus; NAc: nucleus accumbens; Th: thalamus; Hyp: hypothalamus; SS: somatosensory cortex; Cb: cerebellum.

Supplemental Experimental Procedures

Ethical statement. All research involving animals were carried out in accordance with the European directive 86/609/EEC governing animal welfare and protection, acknowledged by the Italian Legislative Decree no. 116, 27 January 1992. Animal research protocols were also reviewed and consented to by a local animal care committee.

Mouse line generation. To enable stable and reproducible pan-neuronal stimulation of 5-HT producing cells, we first generated a conditional knock-in hM3Dq mouse line. The hM3Dq sequence in-frame-fused with the mCherry reporter and flanked by two couples of Lox sites (LoxP and Lox2722, DIO-hM3Dq, Double-floxed Inverse ORF) was isolated by EcoRI digestion from pAAV-hSyn-DIO-hM3Dq construct (a kind gift From Dr. Bryan Roth) and inversely cloned downstream to the CAG promoter in the pCX-CAG-eGFP plasmid, thus replacing the eGFP coding sequence (CDS)(Krashes et al., 2011). The CAG-DIO-hM3Dq fragment was extracted from the pCX-CAG-hM3Dq by a SpeI/XbaI double digestion and cloned into the unique XbaI site placed (Krashes et al., 2011) between the right (RA) and the left (LA) ROSA26 homology arms included in the pROSA26-1^{Sor} plasmid. P_{gk}-Neo/Kana (NEO) and P_{gk}-Diferic Toxin A cassettes (DTA) were used for positive and negative selection, respectively. PvuI-linearized pROSA26-1^{Sor}-LA-CAG-DIO-hM3Dq-NEO-RA-DTA was electroporated in E14Tg2a.4 embryonic stem cells (ESCs) as previously described (Pelosi et al., 2015). Positive recombinants identified by southern blot were microinjected in the host C57BL/6J blastocysts, which were injected in utero of pseudopregnant CD1 females (3.5 dpc) to give rise to chimeras (n=29). Animals were routinely genotyped by PCR DNA amplification with specific oligonucleotides as primers: 5'-GAGGGGAGTGTGCAATACC-3' as forward, and 5'-AGTCTAACTCGCGACACTGTA-3' as reverse, for the wild-type ROSA26 allele; the alternative reverse 5'-GTCCCTATTGGCGTTACTATG-3' for the DIO-hM3Dq allele; 5'-GTCATCTCCTTTGTCCTTTGG-3' as forward and 5'-GGAGCTGGGTTTCCAGCTC-3' as reverse for the hM3Dq CDS. Before chemo-fMRI experiments, animals were backcrossed on C57BL/6J for a least six generations. To enable the expression of hM3Dq in 5-HT producing neurons, mice were then crossed with Pet1₂₁₀-Cre mice (Pelosi et al., 2014, Barrett et al., 2016). The resulting hM3Dq^{+/+}/Pet1-Cre mice were imaged during young adulthood (12-20 weeks). Control studies with CNO and citalopram were carried out using male adult (12-20 weeks) C57BL/6J mice.

Immunohistochemical analyses and cell counting. Mice were deeply anesthetized with avertin 1.25 % and perfused transcardially with 4% paraformaldehyde. Brains were dissected, post-fixed overnight in 4% paraformaldehyde at 4°C and sectioned in slices 50 μm thick by a Leica Microsystems vibratome. In mCherry and Tph2 immunodetection studies, free floating sections were incubated at 4°C overnight with rabbit anti-RFP (ab62341, Abcam, 1:500) and goat anti-Tph2 (ab121020, Abcam, 1:800). Sections were then incubated overnight at 4°C with donkey anti-rabbit (Rhodamine Red, Invitrogen, 1:500) and donkey anti-goat (Alexa Fluor 488, Invitrogen, 1:500). Single and double immunolabelling was carried out on 4 animals encompassing a total number of cells > 4600 cells. Animals employed for c-Fos mapping (study #4, described below) were euthanized ninety minutes after CNO administration and processed as described above for immunohistochemical mapping. Free-floating sections were incubated overnight at room temperature with goat anti-cFos (SC-52-G, Santa Cruz Biotechnology, 1:1000) in a 5% horse inactivated serum solution. Sections were then incubated overnight at 4°C with donkey anti-goat (Alexa Fluor 488, Invitrogen, 1:500). Serial immunostained coronal brain sections were imaged using a Nikon A1 confocal microscope with a 10X or 40X objective. Cell counts analysis was performed using FIJI-ImageJ using the cell-counter tool (https://imagej.net/Cell_Counter). All pictures were randomized before cell counting, and the operator who performed the analysis (SM) was blinded to genotype and treatment.

Brain Slice Electrophysiology. Brains of hM3Dq^{+/+}/Pet1-Cre were sectioned to obtain 300 μm coronal slices encompassing the dorsal raphe nucleus. Slices were submerged in normal, oxygenated aCSF (28-30° C, 2mL/min flow rate) for at least 30 minutes before performing whole-cell patch clamp experiments. Borosilicate electrodes with a pipette filled with internal solution (135 KMeSO₄, 10 KCl, 10 HEPES, 1 MgCl₂, 2 Na₂-ATP, 0.4 Na₃-GTP (pH 7.2-7.3, 280-290 mOsm/kg). were used to patch cells in the DRN. Signals were acquired using a Multiclamp 700B amplifier and analyzed with Clampfit 10.3 software (Molecular Devices, Sunnyvale, CA, USA). The effects of CNO were determined in current clamp mode. After 5 minutes of stable baseline, CNO (10 μM) was bath applied for 10 minutes while recording changes in membrane potential. For excitability experiments, the current threshold (rheobase) necessary to induce cell firing were determined in current clamp mode using a current ramp protocol from 0 to 100 pA. Next, a 10 pA current step protocol from 0 to 200 pA was applied, from which V-I plots were determined (i.e., the number of action potentials vs. current). We confirmed serotonergic identity of patched cells based on their intrinsic electrophysiological properties including lack of time-dependent depolarization in response to hyperpolarizing current pulses (Calizo et al., 2011).

Drug formulation and pharmacological treatments

fMRI experiments were performed using intravenous drug administration. We chose this route of administration to maximize the rate of fMRI signal change, with the aim to induce sharp fMRI responses that can be more easily discriminated from linear alterations in baseline due to scanner, contrast agent elimination or physiological drifts. Clozapine-n-Oxide (Sigma Aldrich) was dissolved in saline solution at a concentration of 0,125 μg/ml. The CNO dose employed for chemo-fMRI mapping (0,5 mg/kg i.v., volume 10 mL/kg) was selected out of dose-response experiments (0,5-1-2 mg/kg i.v.) described in the result section (Fig. S1).

Pilot c-Fos mapping studies in which we used intravenous vehicle administration, showed that the prolonged restriction required for intravenous dosing results in broad unspecific Fos increases with respect to baseline conditions. Because the pharmacokinetic properties of CNO in the mouse have not been described in detail, to account for the reduced bioavailability and lower peak plasma concentrations often associated with intraperitoneal drug dosing (Nemes et al., 2000, Meyer et al., 2008), we empirically adjusted CNO dosing to be used in conscious studies to 2 mg/kg. This decision was also motivated by a pilot fMRI study showing that intraperitoneal dosing of CNO at 2 mg/kg does not substantially alter fMRI baseline signal (Fig. S5; $p > 0.26$ all regions, Student t test, $Z > 1.6$, statistical maps). This dose employed is in line with the amounts of CNO tested by other investigators in DREADD-based studies (Roth, 2016).

Citalopram (Sigma Aldrich) was dissolved in saline solution at a concentration of 3 or 1.5 ml/kg for 10 mg/kg and 5 mg/kg dosing, respectively. The citalopram doses tested were previously shown to be behaviorally effective in C57Bl/6J mice (Browne and Fletcher, 2016).

Functional Magnetic Resonance Imaging (fMRI). Animal preparation for functional magnetic resonance imaging has been previously described in great detail (Ferrari et al., 2012). The protocol utilized is optimized for physiological stability and permits monitoring of peripheral parameters critical to the success of pharmacological fMRI (phMRI), such as peripheral blood pressure (Ferrari et al., 2012) and arterial blood gases. Briefly, mice were anaesthetized with isoflurane (5% induction), intubated and artificially ventilated (2.5% surgery). The left femoral artery was cannulated for continuous blood pressure monitoring and blood sampling. Surgical sites were infiltrated with tetracaine, a non-brain-penetrant local anesthetic (Ferrari et al., 2010). At the end of surgery, the animal was placed in supine position onto a water-heated custom cradle and isoflurane was discontinued and replaced by halothane (0.8%), an anesthetic that preserves cerebral blood flow auto-regulation and neurovascular coupling (Gozzi et al., 2007). Functional data acquisition started 30 minutes after isoflurane cessation. Ventilation parameters were adjusted to maintain arterial $p_a\text{CO}_2$ levels < 40 mmHg (Pepelko and Dixon, 1975) and $p_a\text{O}_2$ levels > 90 mmHg, values which correspond to the 98% of hemoglobin saturation (Supplemental table I).

fMRI data were acquired as previously described (Squillace et al., 2014) on a 7T Pharmascan (Bruker, Ettlingen, Germany) by using a 72-mm birdcage resonator and a 4 channel anatomical shaped Bruker mouse brain coil, placed dorsally to the animal head. Co-centered anatomical and fMRI images were acquired using a Rapid Acquisition Relaxation-Enhanced and a Fast Low-Angle Shot MRI sequence ($T_{\text{Reff}} = 394.7$ ms, $T_{\text{Eeff}} = 3.1$ ms, $\alpha = 30^\circ$; $180 \times 180 \times 600$ μm resolution, $dt = 60$ s, $N_r = 60$ corresponding to 60 min total acquisition time). Images were sensitized to reflect alterations in relative cerebral blood volume (rCBV) by previous administration of 5 $\mu\text{l/g}$ of blood-pool contrast agent (Molday Ion, Biopal, Worcester, MA, USA). Twenty-five minutes later each subject received an intravenous administration of vehicle or drug. fMRI responses were mapped and quantified as previously described (Galbusera et al., 2017). Briefly, fMRI time series were spatially normalized to a common reference space and signal intensity changes were converted into fractional rCBV changes. rCBV time series before and after drug or vehicle injections were extracted and analyzed. Voxel-wise group statistics was performed using FEAT Version 5.63, with 0.5 mm spatial smoothing and using a boxcar input function that captured the main alterations in rCBV signal observed upon pharmacological challenge with respect to vehicle baseline in representative volumes of interest (Figure S1). Specifically, the chemo-fMRI response to 5-HT stimulation was used using a boxcar function covering a 10-28 min post-injection time window, while citalopram was mapped using a boxcar regressor depicting a 0-25 min post injection time window.

The composition of experimental groups was as follows:

Study 1: – CNO dose-response in C57Bl6J mice: intravenous treatment with CNO (0,5 mg/kg $n=6$; 1 mg/kg $n=4$; 2 mg/kg $n=5$) or vehicle ($n=6$).

Study 2: Chemo-fMRI of 5-HT neurons: intravenous treatment with CNO in hM3Dq/Pet1-Cre ($n = 20$), or control DIO/hM3Dq ($n = 14$).

Study 3: fMRI of citalopram in C57Bl6J mice: intravenous injection of citalopram (5 mg/kg $n=8$; 10 mg/kg $n=7$) or vehicle ($n=10$).

Study 4: CNO-induced cFos-mapping in hM3Dq/Pet1-Cre ($n = 5$) or control DIO/hM3Dq mice ($n = 5$).

Study 5: fMRI of intraperitoneal CNO in C57Bl6J mice: intraperitoneal treatment with CNO (2 mg/kg $n=6$) or vehicle ($n=6$).

In vivo electrophysiology

To corroborate a neural origin of the fMRI signal, acute Local Field Potential measurements were performed on a separate cohort of anaesthetised DIO/hM3Dq ($n=5$) or hM3Dq/Pet1-Cre ($n=4$) mice, using the same animal preparation and anaesthetic regimen (halothane 0.8%) employed for fMRI. Surgery and recordings were performed on a standard stereotaxic apparatus as previously described (Mahmud et al., 2011, Galbusera et al., 2017). A glass micropipette (impedance ~ 2 M Ω , filled with ACSF solution) was positioned in the hippocampus using the following stereotaxic

coordinates, 1.5 mm ML, 2.2 mm AP and 1.3 mm DV, corresponding to the location of brain microdialysis probe. A common reference Ag-AgCl electrode was placed on the cortical surface. Electrophysiological signals were amplified 1000-fold (EXT-02F, NPI), band pass filtered (0.1–1000 Hz), and sampled at 5 kHz with 16 bit precision by a National Instruments (NI-usb6251) AD board controlled by custom made LabView software. Line frequency 50 Hz noise was removed by means of a linear noise eliminator (Humbug, Quest Scientific). LFP activity was recorded over a 18 minute time window before CNO and 1 hour after intravenous administration of CNO (0.5 mg/kg i.v.). Spectral analysis was performed on Theta ($6 < \text{Hz} < 12$) and Gamma bands ($30 < \text{Hz} < 80$ Hz). Two consecutive temporal points were binned together to reduced data dimensionality. Intergroup differences were assessed using a slope analysis after linear regression as summary statistics over the whole examined time window as recently described (Galbusera et al., 2017) using GraphPad Prism (GraphPad Software, Inc.).

***In vivo* brain microdialysis**

Microdialysis experiments were performed as recently described (Managò et al., 2016). Briefly, male two-month old hM3Dq/Pet1-Cre mice (n=6) and control DIO/hM3Dq mice (n=6) were anesthetized with Isoflurane and then placed in a stereotaxic frame (2B, 2biological instruments) for probe implantation. Concentric dialysis probes were prepared using AN69 dialyzing membranes (Hospal Dasco, Bologna, Italy). Probes were implanted in the dorsal hippocampus using the same coordinates employed for LFP studies. Microdialysis test sessions were performed during the light phase prior to and after intraperitoneal administration of CNO (2 mg/kg). Probes were connected to PE50 tubes and perfused with Ringer's solution (147.0 mM NaCl, 2.2mM CaCl₂, and 4.0 mM KCl) delivered by a 1.0 ml syringe, operated by a BAS Bee Syringe Pump Controller (BAS West Lafayette, IN, USA), through the dialysis probes at a constant flow rate of 1 $\mu\text{L}/\text{min}$. Dialysate samples (20 μL) were analyzed using HPLC apparatus equipped with a reverse-phase column (C83.5 μm , Waters, USA) and a coulometric electrochemical detector (ESA Coulochem II, Bedford, USA) to quantify 5-HT. The electrodes of the analytical cell were set at -175 mV (oxidation) and $+220$ mV (reduction). The composition of mobile phase was: 50 mM NaH₂PO₄, 0.1 mM Na₂EDTA, 0.5 mM n-octylsulfate and 22% (v/v) methanol, pH 5.7. The sensitivity of the assay for 5-HT was 5 fmol/sample. At the end of each experiment, mice were sacrificed and their brains were removed and stored in formalin (4%) before histological analysis. Brain were cut in serial coronal slices (100 μm) to locate the placement of the microdialysis probe. All the numerical data are given as mean \pm SEM. Data were analyzed by utilizing two-way repeated measures ANOVA.

Pharmacokinetic measurements

Blood samples (100 μl) were collected from 10 male adult (12-20 weeks) C57BL/6J mice at different time point (15-30-60 min). Animal preparation was carried out as previously described for fMRI acquisition, to allow for intravenous administration of CNO (0.5 mg/Kg) under halothane sedation (0.8%). All solvents and chemicals were purchased from Sigma Aldrich (Milano, Italia). Plasma samples were centrifuged for 20 min. A 50 μl aliquot was then transferred into a 96-deepwell plate and added with 150 μl of the extraction solution, consisting of cold acetonitrile spiked with clozapine-d₄ as internal standard. After agitation (3 minutes) the plate was centrifuged at 3000g for 20 minutes at 4°C. 80 μl of supernatant were then transferred in a 96-well plate and added with 80 μl of water. Reference standards of clozapine-N-oxide, clozapine and dimethyl-clozapine were spiked in naïve mouse plasma to prepare a calibration curve over the 1 nM – 10 μM range. Three quality controls samples were also prepared by spiking the compounds in blank mouse plasma to final 20, 200 and 2000 nM concentrations. Calibrators and QCs were extracted with the same extraction solution used for the plasma samples. Plasma levels of clozapine-N-oxide, clozapine and dimethyl-clozapine were monitored on a ACQUITY UPLC/MS TQD system consisting of a TQD (Triple Quadrupole Detector) mass spectrometer equipped with an electrospray ionization interface; 3 μl of each sample were injected on a reversed phase column (Acquity UPLC BEH C18 2.1 X 50 mm, 1.7 μm particle size) and separated with a gradient of acetonitrile (10% to 50% B in two minutes). Column and UPLC-MS system were purchased from Waters Inc. Milford, USA. Flow rate was set 0.5mL/min. Eluents were A = water and B = acetonitrile, both added with 0.1% formic acid. Analysis was performed in ESI+ ionization mode. Compounds were quantified by monitoring their MRM peak areas. The following parameters were used for analyte detection and quantification:

Analyte	Retention Time (minutes)	Precursor m/z	Fragment m/z	Cone voltage (V)	Collision energy (eV)
clozapine-N-oxide	1.87	343	227	30	35
		343	243	30	35
		343	256	35	25
clozapine	1.70	327	227	45	40

		327	270	45	30
		327	296	45	30
demethyl-clozapine	1.57	313	192	45	45
		313	227	45	35
		313	270	45	30
clozapine-d4 (internal standard)	1.70	331	272	45	30

Supplemental References

- BARRETT, K. T., DOSUMU-JOHNSON, R. T., DAUBENSPECK, J. A., BRUST, R. D., KREOUZIS, V., KIM, J. C., LI, A., DYMECKI, S. M. & NATTIE, E. E. 2016. Partial Raphe Dysfunction in Neurotransmission Is Sufficient to Increase Mortality after Anoxic Exposures in Mice at a Critical Period in Postnatal Development. *The Journal of Neuroscience*, 36, 3943-3953.
- BROWNE, C. J. & FLETCHER, P. J. 2016. Decreased Incentive Motivation Following Knockout or Acute Blockade of the Serotonin Transporter: Role of the 5-HT_{2C} Receptor. *Neuropsychopharmacology*, 41, 2566-76.
- FERRARI, L., CRESTAN, V., SABATTINI, G., VINCO, F., FONTANA, S. & GOZZI, A. 2010. Brain penetration of local anaesthetics in the rat: Implications for experimental neuroscience. *Journal of Neuroscience Methods*, 186, 143-149.
- GOZZI, A., CEOLIN, L., SCHWARZ, A., REESE, T., BERTANI, S., CRESTAN, V. & BIFONE, A. 2007. A multimodality investigation of cerebral hemodynamics and autoregulation in pharmacological MRI. *Magnetic Resonance Imaging*, 25, 826-833.
- KRASHES, M. J., KODA, S., YE, C., ROGAN, S. C., ADAMS, A. C., CUSHER, D. S., MARATOS-FLIER, E., ROTH, B. L. & LOWELL, B. B. 2011. Rapid, reversible activation of AgRP neurons drives feeding behavior in mice. *The Journal of Clinical Investigation*, 121, 1424-1428.
- MAHMUD, M., PASQUALOTTO, E., BERTOLDO, A., GIRARDI, S., MASCHIETTO, M. & VASSANELLI, S. 2011. An automated method for detection of layer activation order in information processing pathway of rat barrel cortex under mechanical whisker stimulation. *Journal of Neuroscience Methods*, 196, 141-150.
- MEYER, P. T., SALBER, D., SCHIEFER, J., CREMER, M., SCHAEFER, W. M., KOSINSKI, C. M. & LANGEN, K.-J. 2008. Comparison of intravenous and intraperitoneal [¹²³I]IBZM injection for dopamine D₂ receptor imaging in mice. *Nuclear Medicine and Biology*, 35, 543-548.
- NEMES, K. B., ABERMANN, M., BOJTI, E., GRÉZAL, G., AL-BEHAISI, S. & KLEBOVICH, I. 2000. Oral, Intraperitoneal and Intravenous Pharmacokinetics of Deramciclone and its N-desmethyl Metabolite in the Rat. *Journal of Pharmacy and Pharmacology*, 52, 47-51.

- PELOSI, B., PRATELLI, M., MIGLIARINI, S., PACINI, G. & PASQUALETTI, M. 2015. Generation of a Tph2 Conditional Knockout Mouse Line for Time- and Tissue-Specific Depletion of Brain Serotonin. *PLOS ONE*, 10, e0136422.
- PEPELKO, W. E. & DIXON, G. A. 1975. Arterial blood gases in conscious rats exposed to hypoxia, hypercapnia, or both. *J Appl. Physiol*, 38, 581-587.
- ROTH, BRYAN L. 2016. DREADDs for Neuroscientists. *Neuron*, 89, 683-694.
- SQUILLACE, M., DODERO, L., FEDERICI, M., MIGLIARINI, S., ERRICO, F., NAPOLITANO, F., KRASHIA, P., DI MAIO, A., GALBUSERA, A., BIFONE, A., SCATTONI, M. L., PASQUALETTI, M., MERCURI, N. B., USIELLO, A. & GOZZI, A. 2014. Dysfunctional dopaminergic neurotransmission in asocial BTBR mice. *Transl Psychiatry*, 4, e427.

Supplemental Information Inventory

Supplemental data items

Figure S1, CNO dose response, related to Figure 2.

Figure S2, Temporal profile of mean arterial blood pressure, related to Figure 3 and 4.

Figure S3, rCBV timecourse produced by chemogenetic stimulation of 5-HT neurons, related to figure 3.

Figure S4, Hippocampal LFP recordings, related to Figure 3

Figure S5, rCBV response to intraperitoneal CNO in wild-type mice, related to Figure 3

Figure S6, c-Fos induction and extracellular 5-HT release produced by hM3Dq activation of 5-HT neurons, related to Figure 3

Figure S7, rCBV timecourse produced by intravenous citalopram administration in wild-type mice, related to Figure 4.

Supplemental Experimental Procedures